<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 15, Issue 04, 2023</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>October-December</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2024</Year>
<Month>02</Month>
<Day>14</Day>
</PubDate>
<ArticleType>Pharmaceutics</ArticleType>
<ArticleTitle>Role of regulatory affairs in nanoparticles formulation</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>211</FirstPage>
<LastPage>217</LastPage>
<AuthorList>
<Author>
<FirstName>Amrinder</FirstName>
<LastName>Singh</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI>10.56933/Pharmaspire.2023.15132</DOI>
<Abstract>Nanoparticles are small particles that have a wide range of potential applications, including drug delivery, imaging, and diagnostics. However, the safety and efficacy of nanoparticles are still not fully understood, and there are concerns about their potential to cause toxicity. Regulatory affairs professionals play a key role in ensuring the safety and efficacy of nanoparticles by interpreting and applying regulatory guidelines, conducting safety assessments, and preparing regulatory submissions. They also communicate with regulatory agencies throughout the development and commercialization of nanoparticle products. By carefully performing these tasks, regulatory affairs professionals can help to bring these innovative products to market while protecting the public health. The role of regulatory affairs in nanoparticles formulation is complex and challenging, but it is essential to ensure the safety and efficacy of these innovative products. By carefully performing their duties, regulatory affairs professionals can help to bring these products to market and improve the lives of millions of people.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Novel drug delivery systems, Pharmaceutics, Regulatory affairs, Regulatory bodies</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=15055&title=Role of regulatory affairs in nanoparticles formulation</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1.Land;ouml;benberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000;50:3-12.
2. Tinkle S, McNeil SE, Mand;uuml;hlebach S, Bawa R, Borchard G, Barenholz Y, et al. Nanomedicines: Addressing the scientific and regulatory gap. Ann N Y Acad Sci 2014;1313:35-56.
3. Halwani AA. Development of pharmaceutical nanomedicines: From the bench to the market. Pharmaceutics 2022;14:106.
4. Asif M, Alam M, Alam Q. Future of pharmaceutical marketing in India-an extensive review. Int J Pharma Profess Res 2023;14:164-85.
5. Fahmi HL, Al-Jumaili AA, Younus MM. The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study. Explor Res Clin Soc Pharm 2022;7:100162.
6. Tantray J, Zaid M, Kosey S, Patel A, Sharma AK, Sharma R, et al. Pharmacovigilance: A meta-analysis on ADRS of past and recent tragedy occurred in Gambia. J Pharmacovigil 2023;11:409.
7. Heims E, Moxon S. Mechanisms of regulatory capture: Testing claims of industry influence in the case of Vioxx. In: Regulation and Governance. United States: Wiley; 2023.
8. Ziavrou KS, Noguera S, Boumba VA. Trends in counterfeit drugs and pharmaceuticals before and during COVID-19 pandemic. Forensic Sci Int 2022;338:111382.
9. Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu ZX, Chen ZS, et al. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: Recent progress and future challenges. Front Oncol 2022;12:867655.
10. Andra VV, Pammi SV, Bhat Raju LV, Ruddaraju LK. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience 2022;12:274-91.
11. Xu L, Wang X, Liu Y, Yang G, Falconer RJ, Zhao CX. Lipid nanoparticles for drug delivery. Adv NanoBiomed Res 2022;2:2100109.
12. Ding H, Tan P, Fu S, Tian X, Zhang H, Ma X, et al. Preparation and application of pH-responsive drug delivery systems. J Control Release 2022; 48:206-38.
13. Li H, Zha S, Li H, Liu H, Wong KL, All AH. Polymeric dendrimers as nanocarrier vectors for neurotheranostics.Small 2022;18:e2203629.
14. Jena R, Vishwas S, Kumar R, Kaur J, Khursheed R, Gulati M, et al. Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead. Eur J Pharmacol 2022;931:175173.
15. Liu W, Ma Z, Wang Y, Yang J. Multiple nano-drug delivery systems for intervertebral disc degeneration: Current status and future perspectives. Bioact Mater 2023;23:274-99.
16. Banafar A, Shukla SS, Tiwari SP, Kaur CD, Turkane DR, Thakur AS, et al. Enhancement of bioavailability of some cardiovascular drugs by novel nano-carrier delivery system. Acta Sci Pharm Sci 2022;6:24-32.
17. Sharma A, Shamkhani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, et al. Advances in lung cancer treatment using nanomedicines. ACS Omega 2022;8:10-41.
18. He S, Pan H, Zhang J. Advances of typical mesoporous materials and the application in drug delivery. Mater Res Express 2023;10:042001.
19. Shekhar S, Kumar A, Rana V, Kumar R, Mittal C, Tariyal K. Recent approaches of matrix release tablet in NDDS system. J Res Appl Sci Biotechnol 2023;2:64-71.
20. Deshmukh R. Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system. Mater Today Commun 2023;35:105877.
21. Rahman MM, Islam MR, Akash S, Harun-Or-Rashid M, Ray TK, Rahaman MS, et al. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. Biomed Pharmacother 2022;153:113305.
22. Liu J, Li S, Wang J, Li N, Zhou J, Chen H. Application of nano drug delivery system (NDDS) in cancer therapy: A perspective. Recent Pat Anticancer Drug Discov 2023;18:125-32.
23. Jiang L, Li X, Lu YS. Nano-based drug delivery system in breast cancer treatment. Nano 2023;18:2330003.
24. Patil PJ, Sutar SS, Usman M, Patil DN, Dhanavade MJ, Shehzad Q, et al. Exploring bioactive peptides as potential therapeutic and biotechnology treasures: A contemporary perspective. Life Sci 2022;301:120637.
25. Botros S, Botros M, Botros N. A comparison of the drug approval process in the United States and Canada. Int J Drug Regul Affairs 2022;10:1-8.
26. Zhang S, Zhang S, Luo S, Tang P, Wan M, Wu D, et al. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: Advance and prospect. J Nanobiotechnol 2022;20:1-27.
27. Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev 2022;182:114113.
28. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M.Drug release study of the chitosan-based nanoparticles.Heliyon 2022; 15:4.</References>
</References>
</Journal>
</Article>
</ArticleSet>